Expert consensus on perioperative treatment for non-small cell lung cancer

被引：8

作者：

Duan, Jianchun ^{[1
]}

Tan, Fengwei ^{[2
]}

Bi, Nan ^{[3
]}

Chen, Chun ^{[4
]}

Chen, Ke-Neng ^{[5
]}

Cheng, Ying ^{[6
]}

Chu, Qian ^{[7
]}

Ge, Di ^{[8
]}

Hu, Jie ^{[9
,10
]}

Huang, Yunchao ^{[11
]}

Jiang, Tao ^{[12
]}

Long, Hao ^{[13
]}

Lu, You ^{[14
]}

Shi, Meiqi ^{[15
,16
,17
]}

Wang, Jialei ^{[18
]}

Wang, Qiming ^{[19
]}

Yang, Fan ^{[20
]}

Yang, Nong ^{[21
]}

Yao, Yu ^{[22
]}

Ying, Jianming ^{[23
]}

Zhou, Caicun ^{[24
]}

Zhou, Qing ^{[25
]}

Zhou, Qinghua ^{[26
]}

Bongiolatti, Stefano ^{[27
]}

Brunelli, Alessandro ^{[28
]}

Fiorelli, Alfonso ^{[29
]}

Gobbini, Elisa ^{[30
]}

Gridelli, Cesare ^{[31
]}

John, Thomas ^{[32
]}

Kim, Jae Jun ^{[33
]}

Lin, Steven H. ^{[34
]}

Metro, Giulio ^{[35
]}

Minervini, Fabrizio ^{[36
]}

Novoa, Nuria M. ^{[37
,38
]}

Owen, Dwight H. ^{[39
]}

Rodriguez, Maria ^{[40
]}

Sakanoue, Ichiro ^{[41
]}

Scarci, Marco ^{[42
]}

Suda, Kenichi ^{[43
]}

Tabbo, Fabrizio ^{[44
]}

Tam, Terence Chi Chun ^{[45
]}

Tsuchida, Masanori ^{[46
]}

Uchino, Junji ^{[47
,48
]}

Voltolini, Luca ^{[27
]}

Wang, Jie ^{[1
]}

Gao, Shugeng ^{[2
]}

机构：

[1] Chinese Acad Med Sci & Pelting Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Dept Thorac Surg, Natl Canc Ctr, Canc Hosp,Natl Clin Res Ctr Canc, Beijing, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc,Canc Hosp, Natl Canc Ctr, Dept Radiat Oncol, Beijing, Peoples R China

[4] Fujian Med Univ Union Hosp, Dept Thorac Surg, Fuzhou, Peoples R China

[5] Peking Univ Canc Hosp & Inst, Dept Thorac Surg, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China

[6] Jilin Canc Hosp, Dept Med Oncol, Changchun, Peoples R China

[7] Iivazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China

[8] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, Shanghai, Peoples R China

[9] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R China

[10] Shanghai Geriatr Ctr, Shanghai, Peoples R China

[11] Kunming Med Univ, Canc Ctr Yunnan Prov, Dept Thorac Surg 1,Affiliated Hosp 3, Key Lab Lung Canc Yunnan Prov,Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China

[12] Air Force Med Univ, Tangdu Hosp, Dept Thorac Surg, Xian, Peoples R China

[13] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Thorac Surg, State Key Lab Oncol Southern China, Guangzhou, Peoples R China

[14] Sichuan Univ, Dept Thorac Oncol, West China Hosp, Chengdu, Peoples R China

[15] Nanjing Med Univ, Dept Med Oncol, Jiangsu Canc Hosp, Nanjing, Peoples R China

[16] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing, Peoples R China

[17] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Peoples R China

[18] Fudan Univ, Shanghai Canc Ctr, Dept Thorac Med Oncol, Shanghai, Peoples R China

[19] Zhengzhou Univ, Affiliated Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China

[20] Peking Univ Peoples Hosp, Dept Thorac Surg, Beijing, Peoples R China

[21] Cent South Univ, Dept Lung Canc & Gastroenterol, Hunan Canc Hosp, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China

[22] Xi An Jiao Tong Univ, Dept Med Oncol, Affiliated Hosp 1, Xian, Peoples R China

[23] Chinese Acad Med Sci & Peking Union Med Coll, Dept Pathol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China

[24] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Med Oncol, Shanghai, Peoples R China

[25] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

[26] Sichuan Univ, West China Hosp, Lung Canc Inst, Lung Canc Ctr, Chengdu, Peoples R China

[27] Careggi Univ Hosp, Thorac Surg Unit, Florence, Italy

[28] St James Univ Hosp, Dept Thorac Surg, Leeds, W Yorkshire, England

[29] Univ Campania Luigi Vanvitelli, Thorac Surg Unit, Naples, Italy

[30] Univ Grenoble, CHU Grenoble Alpes, Dept Thorax, La Tronche, France

[31] SG Moscati Hosp, Div Med Oncol, Avellino, Italy

[32] Peter MacCallum Canc Ctr, Dept Med Oncol, 305 Grattan St, Melbourne, Vic, Australia

[33] Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Dept Thorac & Cardiovasc Surg, Seoul, South Korea

[34] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA

[35] Azienda Osped Perugia, Santa Maria della Misericordia Hosp, Med Oncol, Perugia, Italy

[36] Cantonal Hosp Lucerne, Dept Thorac Surg, Luzern, Switzerland

[37] Univ Hosp Salamanca, Salamanca, Spain

[38] Inst Biomed Res Salamanca IBSAL, Salamanca, Spain

[39] Ohio State Univ, Comprehens Canc Ctr, Div Med Oncol, Columbus, OH 43210 USA

[40] Clin Univ Navarra, Dept Thorac Surg, Madrid, Spain

[41] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Kyoto, Japan

[42] Imperial Coll Healthcare NHS Trust, Dept Cardiothorac Surg, London, England

[43] Kindai Univ, Dept Surg, Div Thorac Surg, Fac Med, Osaka, Japan

[44] Univ Turin, San Luigi Gonzaga Hosp, Dept Oncol, Orbassano, Italy

[45] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China

[46] Niigata Univ, Div Thorac & Cardiovasc Surg, Grad Sch Med & Dent Sci, Niigata, Japan

[47] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pulm Med, Kyoto, Japan

[48] Bannan Cent Hosp, Iwata, Shizuoka, Japan

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2022年 / 11卷 / 07期

关键词：

RESPONSE EVALUATION CRITERIA; SOLID TUMORS RECIST; NEOADJUVANT CHEMOTHERAPY; SURVIVAL; OUTCOMES; OSIMERTINIB; MULTICENTER; GUIDELINES; CISPLATIN; THERAPY;

D O I：

10.21037/tlcr-22-527

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-small cell lung cancer (NSCLC) accounts for 85% of all newly diagnosed lung cancer cases. Among patients with NSCLC, about 20% are diagnosed with stage I and II, and 30% with stage III diseases (1). In recent years, the popularity of low-dose computed tomography (CT) screening for thoracic disease has resulted in a higher proportion of early-stage NSCLC cases being diagnosed. The mainstay of treatment for stages I–IIIA NSCLC is radical surgery coupled with neoadjuvant or adjuvant therapy in the appropriate setting (2). In patients with completely resected NSCLC, postoperative adjuvant chemotherapy has been associated with better overall survival (OS) in patients with early-stage disease. However, even for the patients with stage I NSCLC, the 5-year lung cancer-specific mortality rate after radical resection has remained unsatisfactory (3). © Translational Lung Cancer Research. All rights reserved.

引用

页码：1247 / 1267

页数：21

共 50 条

[31] Expert recommendation 2006 for rational second line treatment in non-small cell lung cancer
Hilbe, Wolfgang
Aigner, Kurt
Dittrich, Christian
Eckmayr, Josef
Fiegl, Michael
Flicker, Martin
Forstner, Bernhard
Greil, Richard
Jamnig, Herbert
Krajnik, Gerhard
Lang, Alois
Mohn-Staudner, Andrea
Schinko, Herwig
Studnicka, Michael
Pirker, Robert
Ploner, Ferdinand
Rothmund, Johannes
Schiller, Lothar
August, Zabernigg
Zochbauer-Muller, Sabine
[J]. WIENER KLINISCHE WOCHENSCHRIFT, 2007, 119 (7-8) : 259 - 266
[32] The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Brahmer, Julie R.
Govindan, Ramaswamy
Anders, Robert A.
Antonia, Scott J.
Sagorsky, Sarah
Davies, Marianne J.
Dubinett, Steven M.
Ferris, Andrea
Gandhi, Leena
Garon, Edward B.
Hellmann, Matthew D.
Hirsch, Fred R.
Malik, Shakuntala
Neal, Joel W.
Papadimitrakopoulou, Vassiliki A.
Rimm, David L.
Schwartz, Lawrence H.
Sepesi, Boris
Yeap, Beow Yong
Rizvi, Naiyer A.
Herbst, Roy S.
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[33] Staging of non-small cell lung cancer: consensus, controversies and challenges
van Meerbeeck, JP
[J]. LUNG CANCER, 2001, 34 : S95 - S107
[34] International consensus on radiotherapy in metastatic non-small cell lung cancer
Zhu, Zhengfei
Ni, Jianjiao
Cai, Xuwei
Su, Shengfa
Zhuang, Hongqing
Yang, Zhenzhou
Chen, Ming
Ma, Shenglin
Xie, Conghua
Xu, Yaping
Li, Jiancheng
Ge, Hong
Liu, Anwen
Zhao, Lujun
Rao, Chuangzhou
Xie, Congying
Bi, Nan
Hui, Zhouguang
Zhu, Guangying
Yuan, Zhiyong
Wang, Jun
Zhao, Lina
Zhou, Wei
Rim, Chai Hong
Navarro-Martin, Arturo
Vanneste, Ben G. L.
De Ruysscher, Dirk
Choi, J. Isabelle
Jassem, Jacek
Chang, Joe Y.
Kepka, Lucyna
Kasmann, Lukas
Milano, Michael T.
Van Houtte, Paul
Suwinski, Rafal
Traverso, Alberto
Doi, Hiroshi
Suh, Yang-Gun
Noel, Georges
Tomita, Natsuo
Kowalchuk, Roman O.
Sio, Terence T.
Li, Baosheng
Lu, Bing
Fu, Xiaolong
[J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, : 1763 - 1795
[35] Molecular testing in non-small cell lung cancer: A consensus recommendation
Lai, Gillianne Geet Yi
Cheng, Xin Min
Ang, Yvonne Li'en
Chua, Kevin Lee Min
Samol, Jens
Soo, Ross
Tan, Daniel Shao Weng
Lim, Tony Kiat Hon
Lim, Darren Wan Teck
[J]. ANNALS ACADEMY OF MEDICINE SINGAPORE, 2023, 52 (07) : 364 - 373
[36] Treatment of non-small cell lung cancer (NSCLC)
Zarogoulidis, Konstantinos
Zarogoulidis, Paul
Darwiche, Kaid
Boutsikou, Efimia
Machairiotis, Nikolaos
Tsakiridis, Kosmas
Katsikogiannis, Nikolaos
Kougioumtzi, Ioanna
Karapantzos, Ilias
Huang, Haidong
Spyratos, Dionysios
[J]. JOURNAL OF THORACIC DISEASE, 2013, 5 : S389 - S396
[37] Radiation Treatment of Non-Small Cell Lung Cancer
Zeng, Jing
Rengan, Ramesh
[J]. SEMINARS IN RADIATION ONCOLOGY, 2021, 31 (02) : 95 - 96
[38] The treatment of advanced non-small cell lung cancer
Spiro, SG
Silvestri, GA
[J]. CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (04) : 287 - 291
[39] Pembrolizumab for the treatment of non-small cell lung cancer
Muller, Mirte
Schouten, Robert D.
De Gooijer, Cornedine J.
Baas, Paul
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (05) : 399 - 409
[40] On the pharmacogenetics of non-small cell lung cancer treatment
Santarpia, Mariacarmela
Rolfo, Christian
Peters, G. J.
Leon, Leticia G.
Giovannetti, Elisa
[J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (03) : 307 - 317

← 1 2 3 4 5 →